{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:19:13Z","timestamp":1793837953957,"version":"4.6.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.drudis.2025.104544","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:10:07Z","timestamp":1763374207000},"page":"104544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Choosing pan-HDAC or selective HDAC inhibitors for anticancer therapy"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4668-8248","authenticated-orcid":false,"given":"Shabir Ahmad","family":"Ganai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahreen","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid Ahmad","family":"Padder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104544_b0005","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.drudis.2025.104544_b0010","article-title":"Mechanisms of HDACs in cancer development","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104544_b0015","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.7150\/thno.45922","article-title":"Mitochondrial Sirtuin 3: new emerging biological function and therapeutic target","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2025.104544_b0020","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/emboj\/cdg115","article-title":"HDAC6 interacts with and deacetylates tubulin and microtubules in vivo","volume":"22","author":"Zhang","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2025.104544_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102407","article-title":"Histone deacetylase-10 liberates spermidine to support polyamine homeostasis and tumor cell growth","volume":"298","author":"Stewart","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104544_b0030","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2174\/1568026615666150825125857","article-title":"Histone and non-histone targets of dietary deacetylase inhibitors","volume":"16","author":"Kim","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2025.104544_b0035","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/148201","article-title":"Protein acetylation and the physiological role of HDACs","volume":"2011","author":"Matthias","year":"2011","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2025.104544_b0040","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.drudis.2025.104544_b9000","series-title":"Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy","first-page":"241","article-title":"Futuristic Approaches Towards Designing of Isozyme-Selective Histone Deacetylase Inhibitors Against Zinc-Dependent Histone Deacetylases","author":"Ganai","year":"2020"},{"key":"10.1016\/j.drudis.2025.104544_b0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.chembiol.2014.12.015","article-title":"Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases","volume":"22","author":"Wang","year":"2015","journal-title":"Chem Biol"},{"key":"10.1016\/j.drudis.2025.104544_b0050","doi-asserted-by":"crossref","first-page":"14171","DOI":"10.1021\/acs.jmedchem.5c01677","article-title":"Advancements in hydrazide-based HDAC inhibitors: a review of recent developments and therapeutic potential","volume":"68","author":"Raucci","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104544_b0055","doi-asserted-by":"crossref","first-page":"15171","DOI":"10.1021\/acs.jmedchem.3c01095","article-title":"Discovery of selective histone deacetylase 1 and 2 inhibitors: screening of a focused library constructed by click chemistry, kinetic binding analysis, and biological evaluation","volume":"66","author":"Itoh","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104544_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2025.110695","article-title":"In silico screening of a designed focused chemical space identifies novel alkyl hydrazides as potent HDAC11 inhibitors","volume":"196","author":"Baselious","year":"2025","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.drudis.2025.104544_b0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.drudis.2025.104544_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1563797","article-title":"Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess","volume":"16","author":"Yin","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104544_b0075","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/molecules27030715","article-title":"HDAC inhibitors: innovative strategies for their design and applications","volume":"27","author":"Da\u015bko","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2025.104544_b0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00428-011-1103-0","article-title":"Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC","volume":"459","author":"Quint","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1016\/j.drudis.2025.104544_b0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6890-14-10","article-title":"Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer","volume":"14","author":"Poyet","year":"2014","journal-title":"BMC Clin Pathol"},{"key":"10.1016\/j.drudis.2025.104544_b0090","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.urolonc.2012.06.015","article-title":"Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers","volume":"31","author":"Niegisch","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.drudis.2025.104544_b0095","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2025.104544_b0100","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1349-7006.2001.tb02153.x","article-title":"Expression profile of histone deacetylase 1 in gastric cancer tissues","volume":"92","author":"Choi","year":"2001","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.drudis.2025.104544_b0105","first-page":"769","article-title":"Expression profile of class I histone deacetylases in human cancer tissues","volume":"18","author":"Nakagawa","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2025.104544_b0110","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3892\/ijo.2015.3182","article-title":"The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma","volume":"47","author":"Song","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2025.104544_b0115","first-page":"155","article-title":"Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5","volume":"41","author":"Xu","year":"2018","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.drudis.2025.104544_b0120","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s10565-021-09673-2","article-title":"Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer","volume":"39","author":"Wu","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.drudis.2025.104544_b0125","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3390\/cancers15041039","article-title":"The class IIA histone deacetylase (HDAC) inhibitor TMP269 downregulates ribosomal proteins and has anti-proliferative and pro-apoptotic effects on AML cells","volume":"15","author":"Urwanisch","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104544_b0130","article-title":"Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104544_b0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2010.08301.x","article-title":"Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia","volume":"150","author":"Moreno","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2025.104544_b0140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000334577","article-title":"Histone deacetylase in chronic lymphocytic leukemia","volume":"81","author":"Wang","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.drudis.2025.104544_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064600","article-title":"HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure","volume":"8","author":"Stypula-Cyrus","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104544_b0150","doi-asserted-by":"crossref","unstructured":"Kalle AM, Wang Z. Differential effects of two HDAC inhibitors with distinct concomitant DNA hypermethylation or hypomethylation in breast cancer cells. bioRxiv. Published online March 14, 2019. https:\/\/doi.org\/10.1101\/578062.","DOI":"10.1101\/578062"},{"key":"10.1016\/j.drudis.2025.104544_b0155","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41419-022-04751-7","article-title":"Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression","volume":"13","author":"Hanisch","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104544_b0160","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3892\/mmr.2014.2395","article-title":"Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1","volume":"10","author":"Liu","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.drudis.2025.104544_b0165","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1038\/s41598-019-40054-2","article-title":"Molecular imaging HDAC class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET\/CT\/(MRI) with TFAHA","volume":"9","author":"Laws","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104544_b0170","article-title":"Comprehensive analysis of the differential expression and prognostic value of histone deacetylases in glioma","volume":"10","author":"Li","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.drudis.2025.104544_b0175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2005.02.006","article-title":"Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma","volume":"49","author":"Bartling","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drudis.2025.104544_b0180","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.lungcan.2011.02.019","article-title":"Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung","volume":"74","author":"Minamiya","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drudis.2025.104544_b0185","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1038\/s41598-023-38848-6","article-title":"Histone deacetylase inhibitors inhibit lung adenocarcinoma metastasis via HDAC2\/YY1-mediated downregulation of Cdh1","volume":"13","author":"Wang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104544_b0190","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3892\/or.2016.4811","article-title":"HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma","volume":"36","author":"Wang","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2025.104544_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2023.102250","article-title":"Knockdown of HDAC10 inhibits POLE2-mediated DNA damage repair in NSCLC cells by increasing SP1 acetylation levels","volume":"83","author":"Guo","year":"2023","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104544_b0200","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.biopha.2016.09.030","article-title":"HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin","volume":"84","author":"Li","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2025.104544_b0205","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.oraloncology.2008.08.011","article-title":"Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients","volume":"45","author":"Chang","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.drudis.2025.104544_b0210","first-page":"117","article-title":"Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma","volume":"29","author":"Sakuma","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2025.104544_b0215","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jop.12560","article-title":"Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells","volume":"46","author":"Ahn","year":"2017","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.drudis.2025.104544_b0220","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/4616682","article-title":"Advances in the histone acetylation modification in oral squamous cell carcinoma","volume":"2023","author":"Lu","year":"2023","journal-title":"J Oncol"},{"key":"10.1016\/j.drudis.2025.104544_b0225","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13148-021-01068-8","article-title":"HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10","volume":"13","author":"Li","year":"2021","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.drudis.2025.104544_b0230","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3892\/etm.2020.8697","article-title":"Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma","volume":"20","author":"Li","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.drudis.2025.104544_b0235","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12935-022-02581-3","article-title":"Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1","volume":"22","author":"Yang","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.drudis.2025.104544_b0240","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.18632\/aging.100980","article-title":"Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma","volume":"8","author":"Zeng","year":"2016","journal-title":"Aging"},{"key":"10.1016\/j.drudis.2025.104544_b0245","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-018-0788-2","article-title":"Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d\/PI3K\/AKT\/mTOR and ERK pathways","volume":"9","author":"Cao","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104544_b0250","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.3390\/ijms20123052","article-title":"Class I-histone deacetylase (HDAC) inhibition is superior to pan-HDAC inhibition in modulating cisplatin potency in high grade serous ovarian cancer cell lines","volume":"20","author":"Bandolik","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104544_b0255","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12876-022-02101-7","article-title":"MS275 as class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis","volume":"22","author":"Du","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.drudis.2025.104544_b0260","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/aps.2016.139","article-title":"Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration","volume":"38","author":"Sun","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2025.104544_b0265","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/1535-7163.MCT-15-0618","article-title":"Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms","volume":"15","author":"Pinkerneil","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2025.104544_b0270","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/cancers12020337","article-title":"Combination of decitabine and entinostat synergistically inhibits urothelial bladder cancer cells via activation of FoxO1","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104544_b0275","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.3390\/cancers12113095","article-title":"Liver-targeting class I selective histone deacetylase inhibitors potently suppress hepatocellular tumor growth as standalone agents","volume":"12","author":"Tapadar","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104544_b0280","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.2147\/OTT.S250233","article-title":"HDAC1\/2 inhibitor romidepsin suppresses DEN-induced hepatocellular carcinogenesis in mice","volume":"13","author":"Afaloniati","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2025.104544_b0285","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.1038\/s41467-025-62934-0","article-title":"The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active","volume":"16","author":"Sequera","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104544_b0290","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.21873\/anticanres.16635","article-title":"Targeting SALL4 by entinostat inhibits the malignant phenotype of gastric cancer cells by reducing EMT signaling","volume":"43","author":"Du","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drudis.2025.104544_b0295","first-page":"546","article-title":"The HDAC inhibitor entinostat mediates HER2 downregulation in gastric cancer, providing the basis for its particular efficacy in HER2 amplified tumors and in combination therapies","volume":"56","author":"Zenz","year":"2024","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.drudis.2025.104544_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116257","article-title":"HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer","volume":"225","author":"Jenke","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2025.104544_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107057","article-title":"Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma","volume":"208","author":"El Omari","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.drudis.2025.104544_b0310","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/bloodadvances.2018027409","article-title":"Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study","volume":"3","author":"Garcia-Manero","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2025.104544_b0315","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study","volume":"102","author":"Ribrag","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2025.104544_b0320","doi-asserted-by":"crossref","first-page":"12588","DOI":"10.3390\/ijms241612588","article-title":"Anticancer study of a novel pan-HDAC inhibitor MPT0G236 in colorectal cancer cells","volume":"24","author":"Tsai","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104544_b0325","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1535-7163.MCT-08-0534","article-title":"Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models","volume":"8","author":"Pitts","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2025.104544_b0330","doi-asserted-by":"crossref","first-page":"19590","DOI":"10.1038\/s41598-025-04714-w","article-title":"The hydroxamate based HDAC inhibitor WMJ-J-09 induces colorectal cancer cell death by targeting tubulin and downregulating survivin","volume":"15","author":"Huang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104544_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadva.2021.100034","article-title":"Characterization of the MYB-inhibitory potential of the pan-HDAC inhibitor LAQ824","volume":"2","author":"Yusenko","year":"2022","journal-title":"BBA Adv"},{"key":"10.1016\/j.drudis.2025.104544_b0340","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/bloodadvances.2020003566","article-title":"Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors","volume":"5","author":"Mensah","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2025.104544_b0345","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ijc.22558","article-title":"Histone deacetylase inhibitor suberoylanilide hydroxamic acid (vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells","volume":"121","author":"Kumagai","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2025.104544_b0350","doi-asserted-by":"crossref","first-page":"41615","DOI":"10.1038\/srep41615","article-title":"A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104544_b0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119379","article-title":"Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells","volume":"10","author":"Chun","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104544_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114528","article-title":"Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by promoting antigen presentation","volume":"154","author":"Jia","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104544_b0365","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.20892\/j.issn.2095-3941.2021.0130","article-title":"The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKK\u03b1 and overcomes gefitinib resistance in non-small cell lung cancer","volume":"19","author":"He","year":"2022","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.drudis.2025.104544_b0370","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/ijc.30888","article-title":"Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ","volume":"141","author":"Lee","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2025.104544_b0375","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3892\/ijmm.2013.1451","article-title":"The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expression of specificity protein 1 in oral squamous cell carcinoma","volume":"32","author":"Jeon","year":"2013","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.drudis.2025.104544_b0380","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.oraloncology.2011.07.031","article-title":"Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma","volume":"47","author":"Bai","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.drudis.2025.104544_b0385","first-page":"455","article-title":"The histone deacetylase inhibitor trichostatin A induces G2\/M phase arrest and apoptosis in YD-10B oral squamous carcinoma cells","volume":"27","author":"Anh","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2025.104544_b0390","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.3390\/cancers12123527","article-title":"SAHA overcomes 5-FU resistance in IFIT2-depleted oral squamous cell carcinoma cells","volume":"12","author":"Regmi","year":"2020","journal-title":"Cancers"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:08:22Z","timestamp":1780920502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625002570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1359644625002570"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104544","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choosing pan-HDAC or selective HDAC inhibitors for anticancer therapy","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104544"}}